A detailed history of Jane Street Group, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 32,929 shares of TRVI stock, worth $139,618. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,929
Previous 66,368 50.38%
Holding current value
$139,618
Previous $197,000 44.67%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.58 - $3.51 $86,272 - $117,370
-33,439 Reduced 50.38%
32,929 $109,000
Q2 2024

Aug 14, 2024

BUY
$2.44 - $3.36 $120,228 - $165,560
49,274 Added 288.25%
66,368 $197,000
Q1 2024

May 15, 2024

SELL
$1.3 - $3.7 $63,516 - $180,778
-48,859 Reduced 74.08%
17,094 $58,000
Q4 2023

Feb 14, 2024

BUY
$1.06 - $2.05 $43,834 - $84,773
41,353 Added 168.1%
65,953 $88,000
Q3 2023

Nov 14, 2023

BUY
$2.11 - $2.47 $51,906 - $60,762
24,600 New
24,600 $53,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.